Overview

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

Status:
Completed
Trial end date:
2017-08-18
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate and compare the bioavailability of mesalamine
Phase:
Phase 1
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Treatments:
Mesalamine